banner
 
bar

program

slides
bar
 
 

Basal Insulin in Vulnerable Patients
with Type 2 Diabetes

WebCAST

pre-program survey
We Invite You to Take a Moment and Complete This
Pre-Program Knowledge and Clinical Performance Survey.
Thank You
Viewer Survey
How long did you spend on this program?

Webcast CME Disclosure

Please read this notice and click the acknowledgement
at the bottom of the page to continue.

Program Medium

Internet-based program

Estimated Time to Complete Educational Activity

2.5 hours

Course Overview

In this web-based program, physicians and optometrists will learn how recent developments have helped to advance the management of Type 2 diabetes

Release Date

July 18, 2017

Expiration Date

July 18, 2019

Method of Physician Participation Utilized in Learning Process

There are no fees for participating and receiving CME credit for this activity. During the period July 18, 2017 throughJuly 18, 2019 participants must 1) read the learning objectives and faculty disclosures; 2) study the educational activity, and are expected to view all 9 segments totaling 2.5 hours to successfully complete the activity and earn CME credit; 3) register and complete the evaluation form and post-test; 4) score 100% on the post-test; and 5) print out your CME certificate.

Registration

Participation in this WebCAST is complimentary, and clinicians are invited to view this CME-certified program and/or share this invitation with other colleagues, departmental staff members, and healthcare professionals. 

Grantor Support

Supported by an educational grant from Sanofi Diabetes

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the University of Massachusetts Medical School and CMEducation Resources, LLC. ‘The University of Massachusetts Medical School is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation Statement

University of Massachusetts Medical School designates this enduring activity for a maximum of 2.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Policy on Faculty & Provider Disclosure

University of Massachusetts Medical School requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to University of Massachusetts Medical School policy.  The existence or absence of COI for everyone in a position to control content will be disclosed to participants prior to the start of each activity.

Other Credits

American Nurses Credentialing Center (ANCC) accepts AMA PRA Category 1 Credits™ from organizations accredited by the ACCME.
American Academy of Nurse Practitioners (AANP) accepts AMA PRA Category 1 Credits™ from organizations accredited by the ACCME.
American Academy of Physician Assistants (AAPA) accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credits™ from organizations accredited by the ACCME.

Program Faculty and Disclosure

VIVIAN A. FONSECA, MD, FRCP
Program Chair

Professor of Medicine and Pharmacology
Tulis Tulane Alumni Chair in Diabetes
Chief, Section of Endocrinology
Tulane University Health Sciences Center
New Orleans, LA
 
Research Support (To Tulane): Grants from Asahi, Bayer
Consulting and Speaking: Takeda, Novo Nordisk, Sanofi-aventis, Eli Lilly, Astra-Zeneca, Janssen

 
 
JUAN P. FRIAS, MD, FACE
Clinical Assistant Professor of Medicine
University of California
President
National Research Institute
Los, Angeles, California
 
Consulting: Astra Zeneca, BMS, Johnson and Johnson, Novo Nordisk, Sanofi
Speaker’s Bureau: Sanofi, Eli Lilly, Novo Nordisk, Astra Zeneca
Contracted Research: AbbVie, AstraZeneca, Boehringer Ingelheim, BMS, Elcelyx, Eli Lilly, IONIS, Janssen, Johnson and Johnson, Ligand, Merck, Mylan, Novartis, Novo Nordisk, Pfizer, Sanofi, Theracos, vTv

 
 
GUILLERMO E. UMPIERREZ, MD, CDE
Professor of Medicine
Emory University School of Medicine
Physician
Emory University Hospital/Grady Health System
Atlanta, GA

Nothing to disclose

PABLO F. MORA, MD, MSc, FACE, CDE
Adjunct Associate Professor
University of Texas Southwestern Medical Center at Dallas
Staff Endocrinologist
Diabetes America (Plano)
Plano, Texas

Consultant and Speaker’s Bureau: Novo Nordisk


Educational Objectives

Upon completion of this activity, participants will be able to:

  • Apply national guidelines, including the non-strictly algorithmic and flexibly prescriptive 2012 ADA/ EASD Guidelines focused on comprehensive management of diabetes; and identify therapeutic options, based on objective triggers—number and type of OADs, patient needs and preferences, target goal attainment, and other factors—consisting of oral, basal insulin-, and/or combined oral-insulin regimens that provide guideline-consistent care for this population.
  • Explain the physiologic basis of long-acting insulin formulations and how mimicking physiologic insulin triggers and time-activity profiles may improve efficacy and safety of long-acting formulations;
  • Identify patients with T2D who are not meeting target goals for HbA1 and/or other targets require initiation with or who require intensification with basal insulin therapy;
  • Assess and calculate the risks of hypoglycemia in their patients with T2D, counsel their patients on recognizing symptoms of hypoglycemia, and select among therapeutic agents, including established and longer-acting basal insulin-based therapies and combination oral-insulin-based treatments that may reduce the risk of hypoglycemia in this patient subgroup;
  • Understand how new basal insulin formulations in development or recently introduced into clinical use may help reduce the risk of hypoglycemia associated with insulin use;

Hardware and Software Requirements:

To participate in this program, viewers must have a PC or Macintosh computer that has active, ongoing internet access for the duration of the program, as well as a compatible Flash-viewer. An email address is required for registration, and a printer is required to print out the CME certificate.

Privacy Policy

When you participate in a CME activity offered by CMEducation Resources, we ask you for your name, degree, affiliation, street address, telephone number, fax number, and/or e-mail address (the "Information"). We use that Information in the following ways:

  • We use the Information to grade your post-test and to send you a certificate of completion of the CME activity. If we use a third-party company to grade your post-test and issue certificates of completion, we will give the Information to that company for that purpose only.
  • For each CME activity that you take, you must complete an evaluation questionnaire. That questionnaire asks if you are willing to participate in a follow-up survey. If you answer yes, we will use your name and contact information to send you the survey.
  • We may use the Information to send you information about other CME activities that CMEducation Resources is offering.
  • If our company is acquired by or merged into another company, we may make the Information available to the new owner/entity to use in the ways described above, to enable it to continue our business.
  • You should check this privacy policy periodically to see whether we have made any changes.

Disclaimer

Copyright © 2017 by CMEducation Resources, LLC All rights reserved.

Reproduction, distribution, or translation without express written permission is strictly prohibited.

Content on this webcast reflects the opinions, output, and analyses of experts, investigators, educators, and clinicians whose activities for, while independent, are commercially supported by the sponsor noted at the start of each activity.

Content on this webcast is not meant to be, nor substitute for national guidelines or recommendations generated by professional, academic societies, colleges, or associations.

Content on this webcast is intended for educational value only. Its contents, analyses, and any recommendation made herein are intended to make scientific information and opinion available to health professionals, to stimulate thought, and further investigation. This webcast is not designed nor is any aspect of the contents here intended to provide advice regarding medical diagnosis or treatment for any individual case. Any decisions regarding diagnosis and/or management of any individual patient or group of patients should be made on individual basis after having consulted appropriate sources, whether they be appropriate consultants and/or guidelines and recommendations issued by national organizations, professional societies, governmental health organizations, or similar bodies. This webcast is not intended for use by the layman.

Opinions expressed herein are not necessarily those of CMEducation Resources, LLC, program supporters or accreditors, but reflect the opinions and analyses of the experts who have authored the material. Mention of products or services does not constitute endorsement. Clinical, legal, financial, and other comments are offered for general guidance only; and professional counsel should be sought for all specific situations.

bar

program

slides
bar

I have read this CME information statement and wish to participate in this CME activity.

Copyright © CMEducation Resources, LLC

 
6

 

Key Program Topics Include:

A1c
AACE
AACE/ACE
ACCORD
ADA
ADA/EASD
ADVANCE
Alpha glucosidase inhibitors
Amylin mimetics
Antihyperglycemic
Basal Insulin
biguanides
Biguanides
Bile acid sequentrants
Dapagliflozin
DCCT
Diabetes Dopamine 2 agonists

DPP-4 inhibitor
DPP4 inhibitors
Dyslipidemia
ESRD
Exenatide
FPG
Glargine
Gliclazide
glimiperide
Glomerulus
GLP agonist
GLP1 receptor agonists
Glucose
GLUT2
glyburide
Glycemia
Glycemic
Glycogenolysis 
HbA1c


 

 

HDL
Homeostasis
SGLT2
Hypertension
Hypoglycemia
Hypoglycemia
incretin
Insulin
Insulin detemir
insulinopenia
Kidney
LDL
Meglitines
Metformin
Microalbumin
NHANES
NPH Obesity 
Type 2
Pioglitazone

PPG
prandial
PREMIX
PROACTIVE
SGLT1
Sodium-Glucose Cotransporters
Sulfonlyureas
Sulfonylureas
T2D
T2DM
Thiazolidinedione
troglitazone
TZD
UKPDS
VADT
U300
U100